Skip to Content
Merck
CN

[Therapeutic drug monitoring of levetiracetam].

Therapie (2010-03-09)
Eric Dailly, Régis Bouquié, Danièle Bentué-Ferrer
ABSTRACT

Levetiracetam is an anticonvulsant drug used to treat partial seizures, myoclonic seizures of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. A review of the literature with an evidence-based medicine method highlighted parameters (age, renal failure, pregnancy, combination with other anticonvulsant drugs) which affect levetiracetam pharmacokinetics but no significant relationship between plasma concentration of levetiracetam and efficacy or toxicity. Concentrations usually observed in therapeutics is from 6 to 18 mg/L. However, the determination of an individual therapeutic concentration, associated with an effective and well tolerated therapy, could be recommended particularly before pregnancy. Consequently, therapeutic drug monitoring of levetiracetam which is not currently recommended could be possibly useful in specific clinical situations.

MATERIALS
Product Number
Brand
Product Description

Supelco
Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
USP
Levetiracetam, United States Pharmacopeia (USP) Reference Standard